Compare STEW & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEW | AAPG |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | N/A |
| Metric | STEW | AAPG |
|---|---|---|
| Price | $18.24 | $20.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $48.40 |
| AVG Volume (30 Days) | ★ 83.9K | 16.2K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $290.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.55 | $16.36 |
| 52 Week High | $18.67 | $48.45 |
| Indicator | STEW | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 48.53 |
| Support Level | $18.31 | $18.56 |
| Resistance Level | $18.54 | $27.98 |
| Average True Range (ATR) | 0.20 | 0.67 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 86.49 | 46.46 |
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.